

ORIGINAL ARTICLE

The impact of oral diseases in cirrhosis on complications and mortality

Lea Ladegaard Grønkjær, *^{,†} D Palle Holmstrup,[‡] Peter Jepsen^{*,§} and Hendrik Vilstrup*

Departments of *Hepatology and Gastroenterology, [§]Clinical Epidemiology, Aarhus University Hospital, [†]Department of Gastroenterology, Hospital of South West Jutland, Aarhus and [‡]Section of Periodontology, Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Key words

cirrhosis, disease course, mortality, oral diseases, oral health.

Accepted for publication 31 December 2020.

Correspondence

Lea Ladegaard Grønkjær, Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark. Email: lea.ladegaard.gronkjaer@rsyd.dk

Declaration of conflict of interest: The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Author contribution: Lea Ladegaard Grønkjær, Palle Holmstrup, Peter Jepsen, and Hendrik Vilstrup contributed to the study concept and design; Lea Ladegaard Grønkjær contributed to the acquisition of data; Lea Ladegaard Grønkjær, Palle Holmstrup, Peter Jepsen, and Hendrik Vilstrup contributed to the analysis and interpretation of data; Lea Ladegaard Grønkjær contributed to the drafting of manuscript; Palle Holmstrup, Peter Jepsen, and Hendrik Vilstrup contributed to the critical revision of the manuscript; Lea Ladegaard Grønkjær contributed to the statistical analysis; Lea Ladegaard Grønkjær obtained funding; Palle Holmstrup, Peter Jepsen, and Hendrik Vilstrup contributed to the administrative, technical, or material support; Palle Holmstrup, Peter Jepsen, and Hendrik Vilstrup contributed to the study supervision.

Funding support: A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal

Funding support: Aarhus Universitetshospital

Funding support: Aase & Ejnar Danielsens Foundation

Funding support: Central Denmark Region Foundation for Health Research

Funding support: Novo Nordisk UK Research Foundation

Abstract

Background and Aim: The aims of this study were to describe the prevalence of various oral diseases and to examine the association of the oral diseases with complications and mortality of cirrhosis.

Methods: A total of 184 cirrhosis patients were enrolled and were followed up for 2 years. They underwent oral clinical and radiographic examination. At study entry, the associations between oral diseases with nutrition, inflammation, and cirrhosis complication status were examined. Then, the associations of oral diseases with all-cause and cirrhosis-related mortality were examined using Cox regression to adjust for confounding by age, gender, smoking, alcohol use, alcoholic cirrhosis, cirrhosis complications, comorbidity, Child-Pugh, and Model of End-Stage Liver Disease (MELD) score.

Results: At entry, 26% of the patients had gross caries, 46% periapical lesions, 27% oral mucosal lesions, and 68% periodontitis. Having one or more oral diseases was associated with a higher prevalence of cirrhosis complications (46.7 *vs* 20.5%), higher C-reactive protein (28.5 mg/L *vs* 10.4 mg/L), and higher nutritional risk score (4 *vs* 3). Two-thirds of the patients died during follow-up. The patients with more than one oral disease had an increasingly higher all-cause mortality (two diseases: hazard ratio [HR] 1.55, 95% confidence interval [CI] 1.02–1.98; three and four diseases: HR 1.75, 95% CI 1.05–3.24) and even higher cirrhosis-related mortality (two diseases: HR 1.60, 95% CI 1.01–2.40; three and four diseases: HR 2.04, 95% CI 1.05–8.83) compared to those with no oral disease.

Conclusion: In cirrhosis, having more than one oral disease was associated with more complications and with higher mortality.

294

JGH Open: An open access journal of gastroenterology and hepatology 5 (2021) 294–300

© 2021 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Introduction

Over the past decades, evidence has accumulated to show that oral health is fundamental to general health.¹ Thus, several studies describe an association between oral diseases and cancer, cardiovascular diseases, chronic kidney disease, diabetes mellitus, and rheumatoid arthritis. This body of evidence suggests that oral diseases due to bacterial contamination of the bloodstream and systemic low-grade inflammation may negatively affect the course of systemic diseases, leading to higher morbidity and mortality.²⁻⁵

Likewise, several studies show that patients with cirrhosis have poor oral health with a high prevalence of oral diseases compared to the general population,⁶⁻¹⁰ but the clinical significance in this patient group is still sparsely explored.

In previous studies, we focused on the association of one single oral disease, such as periapical lesions and periodontitis, with the complications and mortality of cirrhosis.¹¹⁻¹³ However, often, patients have more than one oral disease, and the impact of multiple oral diseases on the clinical course of cirrhosis may be greater than that of only one such disease or even exceed the sum of the effects of individual diseases.¹⁴ Thus, an additively negative effect of comorbidity or multimorbidity has been shown on systemic diseases.¹⁵ Therefore, the aims of this study were to describe the prevalence of multiple oral diseases and their associations with cirrhosis complications, inflammation, and nutrition status at study entry in a cohort of cirrhosis patients and to examine the associations between oral diseases singly and in combination and all-cause and cirrhosis-related mortality.

Methods

The patients were consecutively enrolled from March 2013 to November 2015 at the Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark.¹³ All adult men and women with an established diagnosis of cirrhosis based on either liver biopsy and/or on clinical, biochemical, and ultrasonographic findings were included, regardless of whether their admission to the department was acute or scheduled and regardless of cirrhosis etiology and severity. We excluded those who could not speak or understand Danish, had dementia or were cognitively impaired including overt hepatic encephalopathy, had hepatocellular carcinoma or other malignant diseases, or had acute critical conditions. The patient cohort is described in our previous study,¹³ and the present study focuses on the effects of one or more oral diseases on the cohort's clinical course by including long-term follow-up data.

A total of 273 patients were assessed, of whom 89 were excluded due to the exclusion criteria (n = 49), lack of consent (n = 37), or death before the oral and radiographic examinations (n = 3).¹³

Clinical data. Demographics, clinical information, and laboratory results at the time of inclusion were asked or collected from the patients' medical charts, including age, gender, marital status, occupational status, smoker status (current, former, never), present use of alcohol (yes or no) and alcoholic hepatitis, cirrhosis etiology, cirrhosis complication status (episodes of ascites and spontaneous bacterial peritonitis, hepatic encephalopathy, and/or

variceal bleeding), and comorbidity. The comorbidities were classified, and a total score was calculated using the Charlson comorbidity index.¹⁶ Patients' nutritional risk was assessed using the standardized screening tool NRS-2002.¹⁷ To gauge the severity of the cirrhosis disease, the Child-Pugh score and the Model of End-Stage Liver Disease (MELD) score was calculated.¹⁸ The inflammatory marker C-reactive protein (CRP) was obtained from blood samples taken on the day of the oral and radiographic examination, and the number of patients receiving antibiotic treatment was calculated.

All patients were prospectively followed up in the department until death or study termination on 25 November 2018. No patient was lost to follow-up. Dates of death were obtained from the Civil Registration System, an administrative registry continuously updated with vital status and dates of death for all Danish citizens.¹⁹ The cause of death up to and including 2018 was obtained from the Danish Register of Causes of Death, which contains information on all death certificates since 1943.²⁰

At study entry, 12 (7%) of the patients were under evaluation for liver transplantation, and 2 (1%) underwent transplantation during the follow-up.

Oral and radiographic examination. At study entry, clinical and radiographic oral examinations were performed. This included registrations of present teeth and gross caries, that is, with advanced dental decay. Plaque was measured according to the criteria of Silness and Löe.²¹ Furthermore, a periodontal examination including full-mouth registration was completed. The assessment of pocket depth, bleeding on probing, and gingival margin levels were registered at six sites on each tooth. Gingival recession was registered as a negative value. Clinical attachment level was calculated as the sum of the pocket depths and gingival level measurement. Pocket depths and clinical attachment level were rounded to the nearest mm. Periodontitis was defined using the definition developed by the working group of the Centre for Disease Control and Prevention in collaboration with the American Academy of Periodontology.²² Patients with severe or moderate periodontitis were grouped as having periodontitis. Moreover, the examination included an inspection of the oral cavity. Patients' oral mucosa was examined, and any oral mucosal lesion was described.

Three authorized dental hygienists were responsible for the oral examinations, and they were trained by a dentist specialized in periodontitis from the Department of Odontology, Aarhus University. Prior to and halfway through the study, the dental hygienists were calibrated for periodontal registrations. On both occasions, their inter- and intraexaminer reproducibility was assessed by calculation of Lin's concordance correlation coefficient and the degree of agreement according to the categories suggested by McBride.^{23,24} We found moderate to substantial agreement, which was regarded as appropriate for the study purpose.

Periapical status was assessed by digital panoramic radiography, which was taken at the Department of Oral and Maxillofacial Surgery, Aarhus University Hospital, using a Planmeca ProMax 3D. The images were examined in a room with adjustable light using a computer with Planmeca Romexis software. Periapical lesions were defined as the presence of radiolucency in connection with the apical part of the root or widening of the

JGH Open: An open access journal of gastroenterology and hepatology 5 (2021) 294–300

© 2021 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Table 1	Clinical	and	demographical	characteristics	of	the	cirrhosis
patients (<i>i</i>	n = 184)						

Gender, n (%) Male 121 (6) Female 63 (34 Marital status, n (%) Single/divorced/widower 99 (54 Marited/cohabiting 85 (46 Occupational status, n (%) Employed 13 (7) Unemployed 31 (7) Disability pensioner 50 (27) Retired 90 (46 Smoker status, n (%) Current 29 (16) Smoker status, n (%) Current 29 (16) Former 83 (42) Never 72 (35) Alcohol use, n (%) Present alcohol use 70 (36) Present alcohol use 70 (36) No present alcohol use 70 (36) No present alcohol use 14 (6) Patients with alcoholic hepatitis at study 3 (2) entry (Glasgow alcoholic hepatitis 20 (11) Cryptogenic 22 (12) Viral hepatitis B and/or C 8 (4) Cirrhosis complications, n (%) Patients with present cirrhosis-related 66 (36) Complications Acites 44 (24) 1 109 (5) peritonitis at study entry Hepatic encephalopathy 8 (4) Varic	-87)
FemaleG3 (34Marital status, n (%)Single/divorced/widower99 (54Married/cohabiting85 (44Occupational status, n (%)Employed13 (7)Unemployed31 (17)Disability pensioner50 (27)Retired90 (49)Smoker status, n (%)CurrentCurrent29 (16)Former83 (44)Never72 (35)Alcohol use, n (%)Present alcohol usePresent alcohol use70 (38)No present alcohol use70 (38)No present alcohol use70 (38)No present alcohol use70 (38)Socre > 9)Cirrhosis etiology, n (%)Alcohol134 (7)Autoimmune or cholestatic20 (11)Cryptogenic22 (12)Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-relatedComplications66 (36)complications44 (24)Patients with spontaneous bacterial9 (5)peritonitis at study entryHepatic encephalopathyHepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)Charlson comorbidity indexCharlson comorbidity index7 (4)3+24 (13)0Most frequent comorbiditiesDiabetes35 (19)Cirrhosis seeverity, median (range)(14)Chronic lung disease6 (3)Cirrhosis seeverity, median (range)(16)Child-Pugh score </td <td></td>	
Marital status, n (%)Single/divorced/widower99 (54Married/cohabiting85 (46Occupational status, n (%)EmployedEmployed13 (7)Disability pensioner50 (27Retired90 (48)Smoker status, n (%)CurrentCurrent29 (16)Former83 (45)Never72 (35)Alcohol use, n (%)Present alcohol usePresent alcohol use70 (36)Never72 (35)Alcohol use, n (%)Present alcohol usePatients with alcoholic hepatitis at study3 (2)entry (Glasgow alcoholic hepatitis3 (20)entry (Glasgow alcoholic hepatitis3 (20)genes complications, n (%)Patients with present cirrhosis-relatedComplications6 (30)Ascites44 (24)Patients with spontaneous bacterial9 (5)peritonitis at study entry4 (34)Variceal bleeding14 (81)244 (24)1109 (5)0Most frequent comorbidity index7 (4)3+24 (13)21	
Single/divorced/widower99 (54Married/cohabiting85 (46)Occupational status, n (%)EmployedEmployed31 (17)Disability pensioner50 (27)Retired90 (48)Smoker status, n (%)CurrentCurrent29 (16)Former83 (48)Never72 (35)Alcohol use, n (%)Present alcohol usePatients with alcoholic hepatitis at study3 (2)entry (Glasgow alcoholic hepatitisscore > 9)Cirrhosis etiology, n (%)AlcoholAlcohol134 (7)Autoimmune or cholestatic20 (11)Cryptogenic22 (12)Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-relatedComplications6 (36)complications9 (5)Patients with spontaneous bacterial9 (5)peritonitis at study entry8 (4)Variceal bleeding14 (8)Comorbidity, n (%)Charlson comorbidity indexCharlson comorbidity index7 (4)3+24 (13)244 (24)1109 (5)0Most frequent comorbiditiesDiabetes35 (116)Cardiovascular disease36 (116)Cardiovascular disease6 (3)Comorbidity, n (%)Charlson comorbidity index7 (4)3+2214 (214 (24)1109 (5)0Chronic lung diseaseCh	34)
Married/cohabiting 85 (46) Occupational status, n (%) Employed 13 (7) Employed 31 (17) 13 (7) Disability pensioner 50 (27) Retired 90 (48) Smoker status, n (%) Current 29 (16) Current 29 (16) Former 83 (48) Never 72 (38) Alcohol use, n (%) Present alcohol use 70 (38) Present alcohol use 70 (38) (2) entry (Glasgow alcoholic hepatitis at study 3 (2) entry (Glasgow alcoholic hepatitis score > 9) Cirrhosis etiology, n (%) Alcohol 134 (7) Autoimmune or cholestatic 20 (11) Cryptogenic 22 (12) Viral hepatitis B and/or C 8 (4) Cirrhosis complications, n (%) Patients with present cirrhosis-related complications Ascites 44 (24) Patients with spontaneous bacterial 9 (5) 9 peritonitis at study entry Hepatic encephalopathy 8 (4) Variceal bleeding 14 (8) Charlson comorbidity in	
Occupational status, n (%)Employed13 (7)Employed31 (17)Disability pensioner50 (27)Retired90 (48)Smoker status, n (%)CurrentCurrent29 (16)Former83 (48)Never72 (38)Alcohol use, n (%)Present alcohol usePatients with alcoholic hepatitis at study3 (2)entry (Glasgow alcoholic hepatitis70 (38)score > 9)Cirrhosis etiology, n (%)Alcohol134 (7)Autoimmune or cholestatic20 (11)Cryptogenic22 (12)Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-related66 (36)complications44 (24)Patients with spontaneous bacterial9 (5)peritonitis at study entry9Hepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)109 (5)OMost frequent comorbiditiesDiabetes35 (19)Carthovascular disease35 (19)Cardiovascular disease6 (3)Cirthosis severity, median (range)11 (6-3)Child-Pugh score8 (5-1)MELD score11 (6-3)Inflammation status(0.9-101.0)Child-Pugh score8 (5-1)MELD score11 (6-3)Inflammation status(0.9-101.0)C-Reactive Protein Median (range)13.3 mg(0.9-101.0)13.3 mg(
Employed13 (7)Unemployed31 (17)Disability pensioner50 (27)Retired90 (48)Smoker status, n (%)CurrentCurrent29 (16)Former83 (45)Never72 (35)Alcohol use, n (%)Present alcohol usePatients with alcoholic hepatitis at study3 (2)entry (Glasgow alcoholic hepatitisscore > 9)Cirrhosis etiology, n (%)AlcoholAlcohol134 (7)Autoimmune or cholestatic20 (11)Cryptogenic22 (12)Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-related66 (36)complications44 (24)Patients with spontaneous bacterial9 (5)peritonitis at study entryHepatic encephalopathyHepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)Charlson comorbidity index7 (4)3+244 (24)1109 (5)0Most frequent comorbiditiesDiabetes35 (19)Cardiovascular disease31 (16)Renal disease6 (3)Cirrhosis severity, median (range)(1)Child-Pugh score8 (5-1)MELD score11 (6-3)Inflammation status(0,9-101.0)Question (use (1))(1)Patients receiving antibiotic treatment at study entry n (%)Nutritional status, median (range)(13.3 mg <t< td=""><td>46)</td></t<>	46)
Unemployed31 (17Disability pensioner50 (27Retired90 (48)Smoker status, n (%)29 (16)Current29 (16)Former83 (45)Never72 (35)Alcohol use, n (%)70 (38)Present alcohol use70 (38)No present alcohol use70 (38)No present alcohol use114 (6)Patients with alcoholic hepatitis at study3 (2)entry (Glasgow alcoholic hepatitis31 (17)Alcohol134 (7)Autoimmune or cholestatic20 (11)Cryptogenic22 (12)Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-related66 (36)complications26 (4)Complications9 (5)peritonitis at study entry8 (4)Variceal bleeding14 (8)Comorbidity, n (%)109 (51)Charlson comorbidity index7 (4)3+24 (12)1109 (51)0Most frequent comorbiditiesDiabetes35 (19)Cardiovascular disease33 (18)Chronic lung disease11 (6-3)Child-Pugh score8 (5-1)MELD score11 (6-3)Inflammation status(0.9-101.6)C-Reactive Protein Median (range)13.3 mg(0.9-101.6)13.3 mg(0.9-101.6)13.3 mg(0.9-101.6)13.3 mg(0.9-101.6)13.3 mg(0.9-101.6)13.3 mg<	
Disability pensioner50 (27Retired90 (48)Smoker status, n (%)29 (16)Current29 (16)Former83 (45)Never72 (36)Alcohol use, n (%)70 (38)Present alcohol use70 (38)No present alcoholic hepatitis at study3 (2)entry (Glasgow alcoholic hepatitis314 (7)Alcohol134 (7)Alcohol134 (7)Alcohol134 (7)Autoimmune or cholestatic20 (11)Cryptogenic22 (12)Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-related66 (36)complications7 (4)Ascites44 (24)Patients with spontaneous bacterial9 (5)peritonitis at study entry8 (4)Variceal bleeding14 (8)Comorbidity, n (%)7 (4)3+24 (13)244 (24)1109 (53)0Most frequent comorbiditiesDiabetes35 (19)Cardiovascular disease33 (16)Chronic lung disease11 (6)Renal disease6 (3)Cirrhosis severity, median (range)13.3 mg(0.9-101.0)13.3 mgPatients receiving antibiotic treatment at22 (12)Study entry n (%)13.3 mgNutritional status, median (range)13.3 mg(0.9-101.0)21 (2)Patients receiving antibiotic treatment at22 (12)Stud	
Retired90 (45)Smoker status, n (%)Current29 (16)Current29 (16)Former83 (45)Never72 (35)Alcohol use, n (%)Present alcohol use70 (36)Present alcohol use114 (6)Patients with alcoholic hepatitis at study3 (2)entry (Glasgow alcoholic hepatitis3 (2)entry (Glasgow alcoholic hepatitis3 (2)entry (Glasgow alcoholic hepatitis3 (2)entry (Glasgow alcoholic hepatitis3 (2)score > 9)Cirrhosis etiology, n (%)Alcohol134 (7)Autoimmune or cholestatic20 (11)Cryptogenic22 (12)Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-relatedPatients with spontaneous bacterial9 (5)peritonitis at study entry8 (4)Hepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)Charlson comorbidity indexCharlson comorbidity index7 (4)3+24 (13)244 (24)1109 (5)0Most frequent comorbiditiesDiabetes35 (19)Cardiovascular disease6 (3)Cirrhosis severity, median (range)(16, 3)Child-Pugh score11 (6, 3)Inflammation status(0.9-10)C-Reactive Protein Median (range)13.3 mg(0.9-10) (.0)(0.9-10)Patients receiving antibiotic treatment at2	17)
Smoker status, n (%)29 (16Current29 (16Former83 (45Never72 (35Alcohol use, n (%)70 (36Present alcohol use70 (36No present alcohol use114 (6)Patients with alcoholic hepatitis at study3 (2)entry (Glasgow alcoholic hepatitis3 (2)entry (Glasgow alcoholic hepatitis3 (2)entry (Glasgow alcoholic hepatitis3 (2)entry (Glasgow alcoholic hepatitis3 (2)score > 9)21 (2)Cirrhosis etiology, n (%)Alcohol134 (7:Autoimmune or cholestatic20 (11Cryptogenic22 (12Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-related66 (36complications44 (24Patients with spontaneous bacterial9 (5)peritonitis at study entry4 (4)Hepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)Charlson comorbidity indexCharlson comorbidity index7 (4)3+24 (13244 (241109 (52)0Most frequent comorbiditiesDiabetes35 (15)Cardiovascular disease3 (18)Chronic lung disease6 (3)Cirrhosis severity, median (range)13.3 mg (0.9-101.0Child-Pugh score16.5-11MeLD score11.6-3Inflammation status(0.9-101.0	27)
Current29 (16Former83 (45Never72 (35Alcohol use, n (%)Present alcohol use70 (35Patients with alcoholic hepatitis at study3 (2)entry (Glasgow alcoholic hepatitis3 (2)entry (Glasgow alcoholic hepatitis3 (2)entry (Glasgow alcoholic hepatitis3 (2)entry (Glasgow alcoholic hepatitis at study3 (2)entry (Stagow alcoholic hepatitis at study2 (2)Alcohol134 (7)Autoimmune or cholestatic20 (11Cryptogenic22 (12Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-relatedPatients with spontaneous bacterial9 (5)peritonitis at study entry8 (4)Hepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)Charlson comorbidity index7 (4)3+244 (241109 (5)0Most frequent comorbiditiesDiabetes35 (19)Cardiovascular disease33 (18)Chronic lung disease11 (6)Renal disease6 (3)Cirrhosis severity, median (range)13.3 mg (0.9-101.0Patients receiving antibiotic treatment at study entry n (%)22 (12)Nutritional status, median (range)13.3	49)
Former83 (45 NeverNever72 (39Alcohol use, n (%)Present alcohol use70 (38 No present alcohol usePatients with alcoholic hepatitis at study3 (2) entry (Glasgow alcoholic hepatitis score > 9)314 (73 Clirhosis etiology, n (%)Alcohol134 (73 Autoimmune or cholestatic20 (11 CryptogenicCryptogenic22 (12 Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-related complications66 (36 Complications, n (%)Patients with spontaneous bacterial peritonitis at study entry Hepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)Charlson comorbidity index7 (4) 109 (51)3+24 (13 2109 (55) 0Most frequent comorbidities35 (19 Cardiovascular disease35 (19 Cardiovascular diseaseDiabetes35 (19 Cardiovascular disease31 (16 Cardiovascular diseaseCirrhosis severity, median (range)(11 (6-3) Charlos receiving antibiotic treatment at cardiovascular disease22 (12 Cardiovascular diseaseCirrhosis severity, median (range)13.3 mg (0.9-101.0Patients receiving antibiotic treatment at study entry n (%)22 (12 Nutritional status, median (range)	
Never72 (35)Alcohol use, n (%)Present alcohol use70 (36)Present alcohol use114 (6)Patients with alcoholic hepatitis at study3 (2)entry (Glasgow alcoholic hepatitis3 (2)entry (Glasgow alcoholic hepatitis3 (2)entry (Glasgow alcoholic hepatitis3 (2)score > 9)134 (7)Autoimmune or cholestatic20 (11)Cryptogenic22 (12)Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-relatedPatients with present cirrhosis-related66 (36)complications44 (24)Patients with spontaneous bacterial9 (5)peritonitis at study entry8 (4)Variceal bleeding14 (8)Comorbidity, n (%)Charlson comorbidity index7 (4)3+24 (13)244 (24)1109 (5)0Most frequent comorbiditiesDiabetes35 (19)Cardiovascular disease33 (18)Chronic lung disease11 (6)Renal disease6 (3)Cirhosis severity, median (range)13.3 mg (0.9-101.0)Patients receiving antibiotic treatment at study entry n (%)13.3 mg (0.9-101.0)Nutritional status, median (range)13.3 mg (0.9-101.0)Nutritional status, median (range)13.3 mg (0.9-101.0)	16)
Alcohol use, n (%)70 (38Present alcohol use70 (38No present alcohol use114 (6)Patients with alcoholic hepatitis at study3 (2)entry (Glasgow alcoholic hepatitis3 (2)Alcohol134 (7)Autoimmune or cholestatic20 (11Cryptogenic22 (12Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-relatedPatients with spontaneous bacterial9 (5)peritonitis at study entry8 (4)Hepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)7 (4)S+24 (13)244 (24)1109 (52)00Most frequent comorbidities35 (19)00Most frequent comorbidities35 (19)00Most frequent disease36 (3)Cirrhosis severity, median (range)(3.3 mgChronic lung disease11 (6)Renal disease6 (3)Cirrhosis severity, median (range)13.3 mg(0.9-101.09Patients receiving antibiotic treatment at </td <td>45)</td>	45)
Present alcohol use70 (38No present alcohol use114 (6)Patients with alcoholic hepatitis at study entry (Glasgow alcoholic hepatitis score > 9)3 (2)Cirrhosis etiology, n (%)134 (7)Alcohol134 (7)Autoimmune or cholestatic20 (11)Cryptogenic22 (12)Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-related66 (36)complications44 (24)Patients with spontaneous bacterial9 (5)peritonitis at study entry8 (4)Variceal bleeding14 (8)Comorbidity, n (%)Charlson comorbidity indexCharlson comorbidity index7 (4)3+24 (13)244 (24)1109 (52)0Most frequent comorbiditiesDiabetes35 (19)Cardiovascular disease33 (18)Chronic lung disease11 (6)Renal disease6 (3)Cirrhosis severity, median (range)(13,3 mg)Child-Pugh score8 (5-11)MELD score11 (6-3)Inflammation status(0.9-101.0)Patients receiving antibiotic treatment at study entry n (%)22 (12)Nutritional status, median (range)13.3 mg00Nutritional status, median (range)13.3 mg00Nutritional status, median (range)13.3 mg00000000 <t< td=""><td>39)</td></t<>	39)
No present alcohol use114 (6)Patients with alcoholic hepatitis at study entry (Glasgow alcoholic hepatitis score > 9)3 (2)Cirrhosis etiology, n (%)134 (7)Alcohol134 (7)Autoimmune or cholestatic20 (11)Cryptogenic22 (12)Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-related complications66 (36)Ascites44 (24)Patients with spontaneous bacterial peritonitis at study entry Hepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)Charlson comorbidity index7 (4)3+24 (13)244 (24)1109 (5)0Most frequent comorbiditiesDiabetes35 (19)Cardiovascular disease33 (18)Chronic lung disease31 (18)Chronic lung disease31 (18)Child-Pugh score8 (5-1)MELD score11 (6-3)Inflammation status(0.9-101.0)Patients receiving antibiotic treatment at study entry n (%)22 (12)Nutritional status, median (range)13.3 mg (0.9-101.0)Nutritional status, median (range)13.3 mg (0.9-101.0)Nutritional status, median (range)13.3 mg (0.9-101.0)	
Patients with alcoholic hepatitis at study entry (Glasgow alcoholic hepatitis score > 9)3 (2) entry (Glasgow alcoholic hepatitis score > 9)Cirrhosis etiology, n (%)Alcohol134 (7: 2001)Alcohol134 (7: 2001)20011Autoimmune or cholestatic20 (11) C)20011Cryptogenic22 (12)Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-related complications66 (36) complicationsAscites44 (24)Patients with present cirrhosis-related peritonitis at study entry9 (5) peritonitis at study entryHepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)Charlson comorbidity indexCharlson comorbidity index7 (4) 3+244 (24)1109 (52) 0Most frequent comorbidities11 (67)Diabetes35 (19) Cardiovascular diseaseCardiovascular disease6 (3)Cirrhosis severity, median (range)13.3 mg (0.9–101.0)Chalents receiving antibiotic treatment at study entry n (%)22 (12)Nutritional status, median (range)13.3 mg (0.9–101.0)Nutritional status, median (range)13.3 mg (0.9–101.0)	38)
entry (Glasgow alcoholic hepatitis score > 9) Cirrhosis etiology, n (%) Alcohol 134 (7: Autoimmune or cholestatic 20 (11 Cryptogenic 22 (12 Viral hepatitis B and/or C 8 (4) Cirrhosis complications, n (%) Patients with present cirrhosis-related 66 (36 complications 44 (24 Patients with present cirrhosis-related 9 (5) peritonitis at study entry Hepatic encephalopathy 8 (4) Variceal bleeding 14 (8) Comorbidity, n (%) Charlson comorbidity index 7 (4) 3+ 24 (13 2 44 (24 1 09 (53 0 Most frequent comorbidities Diabetes 35 (19 Cardiovascular disease 33 (18 Chronic lung disease 33 (18 Chronic lung disease 11 (6) Renal disease 6 (3) Cirrhosis severity, median (range) Child-Pugh score 8 (5–1: MELD score 11 (6–3 Inflammation status C-Reactive Protein Median (range) 13.3 mg (0.9–101.0 Patients receiving antibiotic treatment at 22 (12 study entry n (%) Nutritional status, median (range)	(62)
entry (Glasgow alcoholic hepatitis score > 9) Cirrhosis etiology, n (%) Alcohol 134 (7: Autoimmune or cholestatic 20 (11 Cryptogenic 22 (12 Viral hepatitis B and/or C 8 (4) Cirrhosis complications, n (%) Patients with present cirrhosis-related 66 (36 complications 44 (24 Patients with present cirrhosis-related 9 (5) peritonitis at study entry Hepatic encephalopathy 8 (4) Variceal bleeding 14 (8) Comorbidity, n (%) Charlson comorbidity index 7 (4) 3+ 24 (13 2 44 (24 1 09 (53 0 Most frequent comorbidities Diabetes 35 (19 Cardiovascular disease 33 (18 Chronic lung disease 33 (18 Chronic lung disease 11 (6) Renal disease 6 (3) Cirrhosis severity, median (range) Child-Pugh score 8 (5–1: MELD score 11 (6–3 Inflammation status C-Reactive Protein Median (range) 13.3 mg (0.9–101.0 Patients receiving antibiotic treatment at 22 (12 study entry n (%) Nutritional status, median (range)	2)
score > 9)Cirrhosis etiology, n (%)Alcohol134 (7:Autoimmune or cholestatic20 (11Cryptogenic22 (12Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-related66 (36complications44 (24Patients with present cirrhosis-related9 (5)peritonitis at study entry9 (5)Hepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)Charlson comorbidity indexCharlson comorbidity index7 (4)3+24 (13)244 (24)1109 (53)0Most frequent comorbiditiesDiabetes35 (19)Cardiovascular disease33 (18)Chronic lung disease11 (6)Renal disease6 (3)Cirrhosis severity, median (range)13.3 mg(0.9-101.0)Patients receiving antibiotic treatment at study entry n (%)Nutritional status, median (range)13.3 mg(0.9-101.0)10.0Patients receiving antibiotic treatment at study entry n (%)Nutritional status, median (range)	
Cirrhosis etiology, n (%) 134 (7: Alcohol 134 (7: Autoimmune or cholestatic 20 (11 Cryptogenic 22 (12 Viral hepatitis B and/or C 8 (4) Cirrhosis complications, n (%) Patients with present cirrhosis-related 66 (36 complications 44 (24 Patients with spontaneous bacterial 9 (5) peritonitis at study entry 8 (4) Variceal bleeding 14 (8) Comorbidity, n (%) 7 (4) Charlson comorbidity index 7 (4) 3+ 24 (13 2 44 (24 1 109 (5) 0 0 Most frequent comorbidities 35 (19 Diabetes 35 (19 Cardiovascular disease 31 (18 Chronic lung disease 11 (6) Renal disease 6 (3) Cirrhosis severity, median (range) 13.3 mg (0.9-101.0) Child-Pugh score 13.3 mg (0.9-101.0) MELD score 11 (6-3) Inflammation status (2) C-Reactive Protein Median (range) 13.3 mg (0.9-101.0)	
Alcohol134 (7)Autoimmune or cholestatic20 (11)Cryptogenic22 (12)Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-related66 (36)Patients with spontaneous bacterial9 (5)peritonitis at study entry9 (5)Hepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)7 (4)Charlson comorbidity index7 (4)3+24 (13)244 (24)1109 (5)00Most frequent comorbidities35 (19)Diabetes35 (19)Cardiovascular disease33 (18)Chronic lung disease11 (6)Renal disease6 (3)Cirhosis severity, median (range)13.3 mg (0.9–101.0)Patients receiving antibiotic treatment at study entry n (%)22 (12)Nutritional status, median (range)13.3 mg (0.9–101.0)Nutritional status, median (range)13.4 mg (2.12)	
Autoimmune or cholestatic 20 (11 Cryptogenic 22 (12 Viral hepatitis B and/or C 8 (4) Cirrhosis complications , n (%) Patients with present cirrhosis-related 66 (36 complications 44 (24 Patients with spontaneous bacterial 9 (5) peritonitis at study entry 8 (4) Variceal bleeding 14 (8) Comorbidity , n (%) 6 Charlson comorbidity index 7 (4) 3+ 24 (13 2 44 (24 1 109 (5) 0 0 Most frequent comorbidities 35 (19 Diabetes 35 (19 Cardiovascular disease 33 (18 Chronic lung disease 11 (6) Renal disease 6 (3) Cirrhosis severity , median (range) 13.3 mg (0.9–101.0 Patients receiving antibiotic treatment at 22 (12 study entry n (%) 13.3 mg (0.9–101.0 Patients receiving antibiotic treatment at 22 (12 Study entry n (%) 13.3 mg (0.9–101.0 Patients receiving antibiotic treatment at 22 (12 study entry n (%) 24.	(73)
Cryptogenic22 (12Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-related66 (36complications44 (24Patients with spontaneous bacterial9 (5)peritonitis at study entry8 (4)Hepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)7 (4)Charlson comorbidity index7 (4)3+24 (13)244 (24)1109 (5)00Most frequent comorbidities35 (19)Diabetes35 (19)Cardiovascular disease33 (18)Chronic lung disease11 (6)Renal disease6 (3)Cirrhosis severity, median (range)13.3 mgChild-Pugh score8 (5-1)MELD score11 (6-3)Inflammation status(0.9-101.0)C-Reactive Protein Median (range)13.3 mg(0.9-101.0)Patients receiving antibiotic treatment at 22 (12)study entry n (%)Nutritional status, median (range)	
Viral hepatitis B and/or C8 (4)Cirrhosis complications, n (%)Patients with present cirrhosis-related66 (36)Patients with present cirrhosis-related66 (36)complications44 (24)Patients with spontaneous bacterial9 (5)peritonitis at study entry8 (4)Hepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)7 (4)3+24 (13)244 (24)1109 (51)0109 (51)Most frequent comorbidities35 (19)Diabetes35 (19)Cardiovascular disease33 (18)Chronic lung disease11 (6)Renal disease6 (3)Cirrhosis severity, median (range)13.3 mgChild-Pugh score13.3 mg(0.9–101.0)13.3 mgPatients receiving antibiotic treatment at22 (12)study entry n (%)Nutritional status, median (range)	
Cirrhosis complications, n (%) Patients with present cirrhosis-related 66 (36 complications Ascites 44 (24 Patients with spontaneous bacterial 9 (5) peritonitis at study entry 8 (4) Hepatic encephalopathy 8 (4) Variceal bleeding 14 (8) Comorbidity, n (%) 7 (4) 3+ 24 (13) 2 44 (24) 1 109 (5) 0 0 Most frequent comorbidities 35 (19) Diabetes 35 (19) Cardiovascular disease 33 (18) Chronic lung disease 11 (6) Renal disease 6 (3) Cirrhosis severity, median (range) 13.3 mg (0.9–101.0) Child-Pugh score 13.3 mg (0.9–101.0) Patients receiving antibiotic treatment at 22 (12) 31.3 mg (0.9–101.0) Patients receiving antibiotic treatment at 22 (12) 3.3 mg (0.9–101.0) Nutritional status, median (range) 13.3 mg (0.9–101.0) Nutritional status, median (range) 13.4 mg (0.9–101.0)	
Patients with present cirrhosis-related complications66 (36 complicationsAscites44 (24 Patients with spontaneous bacterial peritonitis at study entry9 (5) peritonitis at study entryHepatic encephalopathy8 (4) Variceal bleeding14 (8)Comorbidity, n (%)7 (4) 3+24 (13) 2Charlson comorbidity index7 (4) 3+244 (24) 11109 (52) 0Most frequent comorbiditiesDiabetes35 (19) 3 (19)Cardiovascular disease31 (16) 6 (3)Chronic lung disease11 (6) 8 (5-12)MELD score11 (6-3)Inflammation status C-Reactive Protein Median (range)13.3 mg (0.9-101.0)Patients receiving antibiotic treatment at study entry n (%)22 (12)Nutritional status, median (range)13.4 mg (2)Nutritional status, median (range)13.5 mg (2)	.,
complicationsAscites44 (24Patients with spontaneous bacterial9 (5)peritonitis at study entry9 (4)Hepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)7 (4)3+24 (13)244 (24)1109 (52)00Most frequent comorbidities35 (19)Diabetes35 (19)Cardiovascular disease33 (18)Chronic lung disease11 (6)Renal disease6 (3)Cirrhosis severity, median (range)13.3 mgChild-Pugh score13.3 mg(0.9–101.0)13.3 mgPatients receiving antibiotic treatment at study entry n (%)22 (12)Nutritional status, median (range)13.4 mgNutritional status, median (range)13.7 mg	36)
Ascites44 (24Patients with spontaneous bacterial9 (5)peritonitis at study entry8 (4)Hepatic encephalopathy8 (4)Variceal bleeding14 (8)Comorbidity, n (%)7 (4)3+24 (13)244 (24)1109 (52)0109 (52)Most frequent comorbidities35 (19)Diabetes35 (19)Cardiovascular disease33 (18)Chronic lung disease11 (6)Renal disease6 (3)Cirrhosis severity, median (range)13.3 mgChild-Pugh score13.3 mg(0.9–101.0)13.3 mgPatients receiving antibiotic treatment at study entry n (%)22 (12)Nutritional status, median (range)13.4 mg	50)
Patients with spontaneous bacterial 9 (5) peritonitis at study entry 8 (4) Variceal bleeding 14 (8) Comorbidity, n (%) 7 (4) 3+ 24 (13) 2 44 (24) 1 109 (5) 0 0 Most frequent comorbidities 35 (19) Diabetes 35 (19) Cardiovascular disease 33 (18) Chronic lung disease 11 (6) Renal disease 6 (3) Cirrhosis severity, median (range) 11 (6-3) Child-Pugh score 8 (5-1) MELD score 11 (6-3) Inflammation status (0.9-101.0) C-Reactive Protein Median (range) 13.3 mg (0.9-101.0) Patients receiving antibiotic treatment at 22 (12) 2 (12) study entry n (%) Nutritional status, median (range)	24)
peritonitis at study entry Hepatic encephalopathy 8 (4) Variceal bleeding 14 (8) Comorbidity, n (%) 14 (8) Charlson comorbidity index 7 (4) 3+ 24 (13) 2 44 (24) 1 109 (5) 0 0 Most frequent comorbidities 35 (19) Diabetes 35 (19) Cardiovascular disease 33 (18) Chronic lung disease 11 (6) Renal disease 6 (3) Cirrhosis severity, median (range) 11 (6-3) Child-Pugh score 8 (5-1) MELD score 11 (6-3) Inflammation status 0 C-Reactive Protein Median (range) 13.3 mg (0.9-101.0) Patients receiving antibiotic treatment at 22 (12) 21.12 study entry n (%) Nutritional status, median (range)	
Hepatic encephalopathy 8 (4) Variceal bleeding 14 (8) Comorbidity, n (%) 14 (8) Charlson comorbidity index 7 (4) 3+ 24 (13) 2 44 (24) 1 109 (5) 0 109 (5) Most frequent comorbidities 35 (19) Diabetes 35 (19) Cardiovascular disease 33 (18) Chronic lung disease 11 (6) Renal disease 6 (3) Cirrhosis severity, median (range) 11 (6-3) Child-Pugh score 8 (5-1) MELD score 11 (6-3) Inflammation status (0.9-101.0) C-Reactive Protein Median (range) 13.3 mg (0.9-101.0) Patients receiving antibiotic treatment at 22 (12) 21.02 study entry n (%) Nutritional status, median (range)	5)
Variceal bleeding14 (8)Comorbidity, n (%)14Charlson comorbidity index7 (4) $3+$ 24 (13)244 (24)1109 (52)0109 (52)Most frequent comorbidities109 (52)Diabetes35 (12)Cardiovascular disease33 (12)Chronic lung disease11 (6)Renal disease6 (3)Cirrhosis severity, median (range)11 (6-3)Child-Pugh score8 (5-12)MELD score11 (6-3)Inflammation status13.3 mgC-Reactive Protein Median (range)13.3 mg(0.9-101.0)13.3 mgPatients receiving antibiotic treatment at study entry n (%)22 (12)Nutritional status, median (range)13.3 mg	4)
Comorbidity, n (%) Charlson comorbidity index 7 (4) 3+ 24 (13) 2 44 (24) 1 109 (52) 0 0 Most frequent comorbidities 35 (19) Diabetes 35 (19) Cardiovascular disease 33 (18) Chronic lung disease 11 (6) Renal disease 6 (3) Cirrhosis severity, median (range) 6 (5-12) MELD score 11 (6-3) Inflammation status 6 (5-12) C-Reactive Protein Median (range) 13.3 mg (0.9-101.0) Patients receiving antibiotic treatment at 22 (12) 21.12 study entry n (%) Nutritional status, median (range)	
Charlson comorbidity index 7 (4) 3+ 24 (13) 2 44 (24) 1 109 (5) 0 0 Most frequent comorbidities 109 (5) Diabetes 35 (19) Cardiovascular disease 33 (18) Chronic lung disease 11 (6) Renal disease 6 (3) Cirrhosis severity, median (range) 6 Child-Pugh score 8 (5–1) MELD score 11 (6–3) Inflammation status 0 C-Reactive Protein Median (range) 13.3 mg (0.9–101.0) Patients receiving antibiotic treatment at 22 (12) 21.12 study entry n (%) Nutritional status, median (range)	(0)
3+ 24 (13 2 44 (24 1 109 (50 0 109 (50Most frequent comorbidities 109 (50Diabetes 35 (19Cardiovascular disease 33 (18Chronic lung disease 11 (6)Renal disease 6 (3)Cirrhosis severity, median (range)Child-Pugh score 8 (5–11MELD score 11 (6–3)Inflammation status $0.9-101.0$ C-Reactive Protein Median (range) 13.3 mg (0.9–101.0)Patients receiving antibiotic treatment at 22 (12)study entry n (%)Nutritional status, median (range)	4)
2 44 (24 1 109 (53) 0 0 Most frequent comorbidities 35 (19) Diabetes 35 (19) Cardiovascular disease 33 (18) Chronic lung disease 11 (6) Renal disease 6 (3) Cirrhosis severity, median (range) 6 Child-Pugh score 8 (5–13) MELD score 11 (6–3) Inflammation status 11 (6–3) C-Reactive Protein Median (range) 13.3 mg (0.9–101.0) Patients receiving antibiotic treatment at 22 (12) 21.12 study entry n (%) Nutritional status, median (range)	
1 109 (5) 0 Most frequent comorbidities Diabetes 35 (19) Cardiovascular disease 33 (18) Chronic lung disease 11 (6) Renal disease 6 (3) Cirrhosis severity, median (range) 6 Child-Pugh score 8 (5–1) MELD score 11 (6–3) Inflammation status 11 (6–3) C-Reactive Protein Median (range) 13.3 mg (0.9–101.0) Patients receiving antibiotic treatment at 22 (12) 21.12 study entry n (%) Nutritional status, median (range)	
0 Most frequent comorbidities Diabetes 35 (19) Cardiovascular disease 33 (18) Chronic lung disease 111 (6) Renal disease 6 (3) Cirrhosis severity, median (range) Child-Pugh score 8 (5–11) MELD score 111 (6–3) Inflammation status C-Reactive Protein Median (range) 13.3 mg (0.9–101.0 Patients receiving antibiotic treatment at 22 (12) study entry <i>n</i> (%) Nutritional status, median (range)	
Most frequent comorbidities Diabetes 35 (19) Cardiovascular disease 33 (18) Chronic lung disease 11 (6) Renal disease 6 (3) Cirrhosis severity, median (range) 6 Child-Pugh score 8 (5–11) MELD score 11 (6–3) Inflammation status 0.9–101.0 C-Reactive Protein Median (range) 13.3 mg (0.9–101.0) Patients receiving antibiotic treatment at 22 (12) 21.12 study entry n (%) Nutritional status, median (range)	(59)
Diabetes 35 (19) Cardiovascular disease 33 (18) Chronic lung disease 11 (6) Renal disease 6 (3) Cirrhosis severity, median (range) 6 Child-Pugh score 8 (5–12) MELD score 11 (6–3) Inflammation status 0.9–101.0 C-Reactive Protein Median (range) 13.3 mg (0.9–101.0) Patients receiving antibiotic treatment at study entry n (%) 22 (12) Nutritional status, median (range) 13.4 mg (0.9–101.0)	
Cardiovascular disease 33 (16 Chronic lung disease 11 (6) Renal disease 6 (3) Cirrhosis severity, median (range) 6 Child-Pugh score 8 (5–12) MELD score 11 (6–3) Inflammation status 0.9–101.0 C-Reactive Protein Median (range) 13.3 mg (0.9–101.0) Patients receiving antibiotic treatment at study entry n (%) 22 (12) Nutritional status, median (range) 12.12	
Chronic lung disease11 (6)Renal disease6 (3)Cirrhosis severity, median (range) $(5-1)$ Child-Pugh score8 (5-1)MELD score11 (6-3)Inflammation status $(0.9-101.0)$ C-Reactive Protein Median (range)13.3 mg(0.9-101.0) $(0.9-101.0)$ Patients receiving antibiotic treatment at22 (12)study entry n (%)Nutritional status, median (range)	
Renal disease 6 (3) Cirrhosis severity, median (range) 8 (5–1: Child-Pugh score 8 (5–1: MELD score 11 (6–3) Inflammation status (0.9–101.0) C-Reactive Protein Median (range) 13.3 mg (0.9–101.0) (0.9–101.0) Patients receiving antibiotic treatment at study entry n (%) 22 (12) Nutritional status, median (range) 13.3 mg	
Cirrhosis severity, median (range) 8 (5–1: Child-Pugh score 8 (5–1: MELD score 11 (6–3) Inflammation status (0.9–101.0) C-Reactive Protein Median (range) 13.3 mg (0.9–101.0) (0.9–101.0) Patients receiving antibiotic treatment at study entry n (%) 22 (12) Nutritional status, median (range) 13.3 mg	
Child-Pugh score 8 (5–1): MELD score 11 (6–3) Inflammation status (0.9–101.0) C-Reactive Protein Median (range) 13.3 mg (0.9–101.0) (0.9–101.0) Patients receiving antibiotic treatment at study entry n (%) 22 (12) Nutritional status, median (range) 100	3)
MELD score 11 (6–3 Inflammation status C-Reactive Protein Median (range) 13.3 mg (0.9–101.0 Patients receiving antibiotic treatment at 22 (12 study entry <i>n</i> (%) Nutritional status, median (range)	
Inflammation status C-Reactive Protein Median (range) Patients receiving antibiotic treatment at study entry <i>n</i> (%) Nutritional status, median (range)	-12)
C-Reactive Protein Median (range) (0.9–101.0 Patients receiving antibiotic treatment at study entry <i>n</i> (%) Nutritional status, median (range)	–37)
(0.9–101.0 Patients receiving antibiotic treatment at 22 (12 study entry <i>n</i> (%) Nutritional status , median (range)	
Patients receiving antibiotic treatment at 22 (12 study entry <i>n</i> (%) Nutritional status , median (range)	ng/L
study entry <i>n</i> (%) Nutritional status , median (range)	1.0 mg/L
Nutritional status, median (range)	12)
-	
Nutritional Dials Coord	
Nutritional Risk Score 3 (1–7	-7)

Table	1	(Continued)

Mortality, n (%)	
Deaths during follow-up	123 (67)
Causes of death	
Cirrhosis-related	101 (82)
Cardiovascular	8 (7)
Infection	4 (3)
Nonhepatic malignancy	3 (2)
Lung disease	2 (2)
Kidney insufficient	2 (2)
Unknown	2 (2)
Pancreatic insufficiency	1 (0.8)

Data are presented as number and percentage or median and range. MELD, Model of End-Stage Liver Disease.

apical part of the periodontal ligament space to greater than twice the normal width.²⁵ A senior resident in oral and maxillofacial surgery examined and described the radiographies after training at the Department of Odontology, Aarhus University.

Ethical considerations. The study was conducted in accordance with the Helsinki Declaration and approved by the Ethical Committee of Central Denmark Region (journal No. 1-10-72-128-12). Written informed consent was obtained from all participants. The participants were informed about their oral health status. In case of oral diseases or problems, the patient was recommended to contact a dentist for appropriate treatment.

Data analysis. A categorical variable was calculated to combine the presence of four oral diseases (i.e. gross caries, oral mucosal lesions, periapical lesions, and periodontitis). This variable was classified as follows: no oral disease and one, two, three, and four oral diseases. Having three and four oral diseases was merged as only five patients had all four oral diseases, leaving four categories. The chi-square test was performed to examine the association between no or one or more oral diseases and patients' gender, smoker status, alcohol use, cirrhosis etiology, and present cirrhosis complications. Due to nonnormally distributed data, the Kruskal-Wallis test was performed to examine the association between no or one or more oral diseases and patients age, comorbidities, cirrhosis severity, CRP, and nutritional risk score. To examine the association of oral diseases with mortality, a categorical all-cause mortality variable, grouping alive and dead patients, was calculated. In addition, a cirrhosis-related mortality variable was calculated. Cirrhosis-related deaths were grouped as those patients with cirrhosis (K70.3, K74.6) or liver failure (K.70.4, K72) listed as the cause of death or as part of the events leading to death. All other deaths were classified as not cirrhosis related. Then, two sets of analyses were performed. First, a Cox proportional hazard regression analysis was used to estimate the association between the presence or absence of each one of the four oral diseases and all-cause and cirrhosis-related mortality. Second, Cox proportional hazards regression analysis was used to explore the association between the categorical oral disease variable and all-cause and cirrhosis-related mortality. The analysis was adjusted for confounding by age, male gender,

JGH Open: An open access journal of gastroenterology and hepatology 5 (2021) 294–300

© 2021 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. Table 2 Oral health characteristics of the cirrhosis patients

Dental status	
Number of teeth, median (IQR)	22 (6–27)
Edentulous patients (%)	18
Prevalence of gross caries in all	6
examined teeth (%)	
Patients with gross caries (%)	26
Periodontal status	
Sites with plaque (%)	89
Probing depth, mm, median (IQR)	3.02 (2.28–3.56)
Clinical attachment level, mm, median (IQR)	3.47 (2.60-4.04)
Sites with bleeding on probing (%)	39
Patients with severe periodontitis (%)	45
Patients with moderate periodontitis (%)	39
Patients with no-or-mild periodontitis (%)	16
Oral mucosal status (%)	
Patients with oral mucosal lesions	27
(all diagnoses)	
Candidiasis	56
Oral mucosal ulcers	24
Fissured or geographic tongue	20
Periapical status	
Prevalence of periapical lesions in all	4
examined teeth (%)	
Patients with periapical lesions (%)	46

Data are presented as percentage or median and interquartile range. IQR, interquartile range.

smoker status, alcohol use, cirrhosis complications, comorbidity, and Child-Pugh and MELD scores. Age, Charlson comorbidity index, Child-Pugh, and MELD score were included as continuous, linear variables. The proportional hazards assumption was evaluated graphically using log–log plots of the survival curves. We used the cumulative incidence function to compute the cumulative all-cause and cirrhosis-related mortality, taking into account that they were competing risks.²⁶ The data were analyzed using Stata version 12.0 (Stata Corp LP, College Station, TX, USA).

Results

The median age of the 184 patients was 62 years (range 21-87), and two-thirds were men (66%). The total follow-up time was 427 years, with a median of 2 years per patient. During follow-

Table 3	Association	of oral	diseases	with	cirrhosis	complications
---------	-------------	---------	----------	------	-----------	---------------

up, 123 patients (67%) died, whereas 101 (82%) died from cirrhosis-related causes, including 3 from hepatocellular carcinoma. Twenty-two patients (18%) died from other causes, with the most common being cardiovascular, infection or nonhepatic malignancy. Patients' clinical and demographic characteristics are summarized in Table 1.

Oral diseases. Table 2 shows the oral health characteristics of the patients. The median number of teeth was 22, and 18% of the patients were edentulous. At entry, 26% had one or more teeth with gross caries (range 1–17), 46% had one or more teeth with periapical lesions (range 1–9), and 27% had one or more oral mucosal lesions. Most common of these were oral candidiasis (56%) and oral mucosal ulcers (24%). Furthermore, 68% had periodontitis. Of the patients, 24% had no oral disease, while 33% had one oral disease, 25% had two, 15% had three, and 3% had four oral diseases.

There were no differences in age, gender, smoker status, alcohol use, comorbidity, and cirrhosis severity in patients with one or more oral diseases compared to patients with no oral disease. However, there was a tendency that more patients with alcoholic cirrhosis had one or more oral diseases compared with nonalcoholic cirrhosis (81 vs 61%, P = 0.07).

Cirrhosis complications. Sixty-six patients (36%) had cirrhosis complications such as ascites (24%), hepatic encephalopathy (4%), and/or variceal bleeding (8%). Patients' median nutritional risk score was 3, and their median CRP was 13.3 mg/L. Having one and up to four oral diseases compared with no oral disease was associated with the presence of more cirrhosis complications (46.7 vs 20.5%), higher CRP (28.5 vs 10.4 mg/L), and nutritional risk score (4 vs 3) (Table 3).

Mortality. The presence of gross caries, oral mucosal lesions, periapical lesions, and periodontitis compared to no oral disease was associated with higher all-cause mortality (gross caries: adjusted hazard ratio (HR) 1.10, 95% confidence intervals (CI) 0.99–1.05; oral mucosal lesions: adjusted HR 1.27, 95% CI 1.01–1.91; periapical lesions: adjusted HR 1.54, 95% CI 0.99–1.79; periodontitis: adjusted HR 2.23, 95% CI 1.10–4.92) and cirrhosis-related mortality (gross caries: adjusted HR 1.26, 95% CI 0.75–2.09; oral mucosal lesions: adjusted HR 1.60, 95% CI 1.03–2.51; periapical lesions: adjusted HR 1.64, 95% CI 0.87–3.08; periodontitis: adjusted HR 3.19, 95% CI 1.14–8.90) (Table 4).

	Ascites, hepatic encephalopathy, and/or variceal bleeding (%)	C-Reactive protein (IQR)	Nutritional risk score (IQR)
No oral disease	20.5%	10.4.1 mg/L (3.4 mg/L-61.5 mg/L)	3 (2–5)
One oral disease	32.6%	12.1 mg/L (5.8 mg/L-58.5 mg/L)	3 (2–5)
Two oral diseases	42.0%	14.5 mg/L (6.7 mg/L-76.3 mg/L)	4 (2–6)
Three and four oral diseases	46.7%	28.5 mg/L (8.0 mg/L-132.5 mg/L)	4 (3–7)
<i>P</i> -value	0.04	0.03	0.07

Data are presented as percentage or median and interquartile range.

IQR, interquartile range.

JGH Open: An open access journal of gastroenterology and hepatology 5 (2021) 294–300

© 2021 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Table 4 Oral disease and risk of mortality

	All-cause	mortality	Cirrhosis-related mortality		
	Crude HR (95% CI)	Adjusted HR (95% CI)	Crude HR (95% CI)	Adjusted HR (95% CI)	
Gross caries versus no gross caries ($n = 151$)	1.06 (0.67–1.69)	1.10 (0.99–1.05)	1.21 (0.74–1.97)	1.26 (0.75–2.09)	
Oral mucosal lesions <i>versus</i> no oral mucosal lesions $(n = 184)$	1.72 (1.16–2.54)*	1.27 (1.01–1.91)*	1.94 (1.28–2.95)*	1.60 (1.03–2.51)*	
Periapical lesions <i>versus</i> no periapical lesions ($n = 110$) Periodontitis <i>versus</i> no periodontitis ($n = 151$)	1.85 (1.09–3.13)* 3.22 (1.49–6.97)*	1.54 (0.99–1.79) 2.23 (1.10–4.92)*	1.99 (1.10–3.57)* 4.16 (1.68–12.63)*	1.64 (0.87–3.08) 3.19 (1.14–8.90)*	

**P* < 0.05.

Associations are expressed as HR with CI and presented without adjustment and with adjustment for age, gender, smoker status, alcohol use, alcoholic cirrhosis, comorbidity, and Child-Pugh and MELD scores.

CI, confidence interval; HR, hazards ratios; MELD, Model of End-Stage Liver Disease.

Table 5	Multiple oral dise	ase and risk of all-caus	se and cirrhosis-related mortality
---------	--------------------	--------------------------	------------------------------------

	All-cause	e mortality	Cirrhosis-related mortality		
	Crude HR (95% CI)	Adjusted HR (95% CI)	Crude HR (95% CI)	Adjusted HR (95% CI)	
One oral disease <i>versus</i> no oral disease	1.10 (0.67–1.20)	1.05 (0.63–1.76)	1.08 (0.60–1.93)	1.01 (0.55–2.40)	
Two oral diseases versus no oral disease	1.51 (1.01–2.67)*	1.55 (1.02–1.98)*	1.81 (1.06–3.37)*	1.60 (1.01–2.40)*	
Three and four oral diseases <i>versus</i> no oral disease	1.59 (1.16–2.67)*	1.75 (1.05–3.24)*	1.89 (1.31–3.35)*	2.04 (1.05–8.83)*	

**P* < 0.05.

Associations are expressed as HR with CI and presented without adjustment and with adjustment for age, gender, smoker status, alcohol use, alcoholic cirrhosis, comorbidity, and Child-Pugh and MELD scores.

CI, confidence interval; HR, hazards ratios; MELD, Model of End-Stage Liver Disease.

When combining the oral diseases into one variable, patients with any single one of the four oral diseases had the same all-cause and cirrhosis-related mortality as the patients with no oral disease (all-cause: adjusted HR 1.05, 95% CI 0.33–1.76; cirrhosis-related: adjusted HR 1.01, 95% CI 0.55–2.40) (Table 5). The patients with more than one oral disease had an increasingly higher all-cause mortality (two diseases: adjusted HR 1.55, 95% CI 1.02–1.98; three and four diseases: adjusted HR 1.75, 95% CI




Figure 1 Cirrhosis-related mortality caused by oral diseases. (-----), No oral disease; (----), two oral diseases; (----), one oral disease; (-----), three and four oral diseases.

1.05–3.24) and an even higher cirrhosis-related mortality (two diseases: adjusted HR 1.60, 95% CI 1.01–2.40; three and four diseases: adjusted HR 2.04, 95% CI 1.05–8.83) compared to the patients with no oral disease (Table 5 and Fig. 1).

Discussion

This cohort study showed that cirrhosis patients had highly prevalent multiple oral diseases, which were associated with increases in cirrhosis complications, CRP, and nutritional risk score. In addition, the presence of more than one oral disease was associated with higher all-cause and cirrhosis-related mortality, increasing with the number of diseases.

The most important strengths of our study are its prospective design, the systematic and detailed oral and radiographic examination, and the complete follow-up. It is also a strength that we studied a broad spectrum of cirrhosis patients with regard to etiology and severity. The distributions of age, gender, and cirrhosis etiology correspond to recent Danish nationwide studies.^{27,28} In addition, only a few patients had alcoholic hepatitis and spontaneous bacterial peritonitis and were receiving antibiotic treatment at study entry, which may have affected their short-term mortality. A large fraction of the patients were classified as having cryptogenic cirrhosis, which may reflect non-alcoholic steatohepatitis. However, this does not affect the results of this study. In addition, although we recruited from both local and referred patients, it remains a limitation that it is a single-center study. Another limitation is the study design, which implies that it cannot be concluded that more oral diseases were in fact the cause of more complications and higher mortality or whether the oral diseases resulted from more advanced disease course. However, the lack of association at study entry between the Child-Pugh and MELD scores and the presence of oral diseases favor the first assumption. We controlled for obvious confounding by statistical adjustments. We did not control for socioeconomic status, and although the Danish population is more homogenous with respect to income and disability status than most other countries,^{27,29} we may have missed an aggravating effect of severe social deprivation.

Our study has no healthy control cohort, and our findings rely on internal analyses, with patients without oral disease serving as sick controls. The prevalence of oral diseases in our cohort was in line with other studies of cirrhosis patients⁶⁻¹⁰ but was very high compared to descriptions of the general population.^{30,31} However, this comparison is uncertain because of variations in the reported background population in sampling procedures and the diagnostic criteria for oral diseases.

There was a tendency that patients with alcoholic cirrhosis had more oral diseases than those with non-alcoholic cirrhosis. This is consistent with findings from other studies^{9,10,32} that consider non-alcoholic cirrhosis patients to be more health conscious than those with alcoholic cirrhosis. However, autoimmune and cholestatic liver diseases are related to Sjögren's syndrome, which may cause oral dryness and favors oral diseases.¹¹

The presence of multiple oral diseases was associated with higher CRP, indicating a degree of systemic inflammation activation beyond that associated with cirrhosis itself. A possible mechanism behind this includes bacterial translocation.^{2,33,34} This may conceivably act as a pathogenic link in the development of more cirrhosis complications and higher mortality, which explains our current and former findings.^{12,13}

In addition, the subgingival microbiota in cirrhosis patients seems to be markedly changed to include bacteria not normally associated with oral diseases. The acquired immune defect of cirrhosis seems to allow commensal bacteria to prevail and become pathogenic. Likewise, the immune defect may predispose patients to oral candidiasis.³⁵

The presence of multiple oral diseases tended to be associated with an increased nutritional risk score. It is plausible that such diseases negatively impact the patients' food intake, contributing to the risk of malnutrition, a major and partly unexplained complication of cirrhosis, leading to higher morbidity and mortality.^{32,36}

The follow-up part of our study demonstrates that periodontitis was associated with a higher risk of mortality compared to the other oral diseases. In studies of patients with cardiovascular diseases and diabetes mellitus, it has been suggested that periodontitis may lead to more complications and higher mortality due to spreading of oral bacteria and bacterial products, either by aspiration or through the bloodstream. Likewise, spillover of inflammatory cytokines may induce and perpetuate systemic effects.^{2,3,9} It may very well be the same for patient with cirrhosis.

The follow-up part also showed that the presence of multiple oral diseases was linked to higher all-cause mortality, largely driven by higher cirrhosis-related mortality, an effect increasing with the number of oral diseases. This is in accordance with other studies suggesting oral disease as a 'nontraditional' prognostic factor influencing the clinical course of liver disease.^{37,38} The one-disease threshold and dose-dependent effect of multiple oral diseases we describe have not previously been investigated in patients with cirrhosis but are consistent with studies of patients with chronic kidney disease.³⁹

The mechanisms behind the linking of oral disease to the worsening of cirrhosis needs further investigations, but the prevalence part of our study may direct attention toward inflammation activation and malnutrition, leading to worse disease course. Anyway, our findings show that more clinical attention should be directed toward oral health status and care. We have shown that cirrhosis patients live with oral hygiene neglect,³² but currently, only patients awaiting liver transplantation are undergoing an oral and radiographic examination. There is a need to evaluate the effect of improved oral care in intervention studies. Promising results are described in a small pilot study of hepatitis C patients,⁴⁰ and a recent study indicates an improvement in oral and gut microbiota dysbiosis, cirrhosis severity, and systemic inflammation activation after improved oral care and treatment by simple means.⁴¹ It is worth noting that two-thirds of our patients died during the relatively short observation time, so there is an urgent need for all sorts of interventions, such as oral care, that may improve this dismal prognosis.

This cohort study provides new information to the sparse knowledge of the clinical significance of oral diseases in patients with cirrhosis that we had sought earlier.⁴² In conclusion, the patients had a high prevalence of various oral diseases, which was associated with the higher presence of cirrhosis complication status and higher CRP and nutritional risk score. Moreover, during follow-up, the presence of more than one oral disease was associated with higher all-cause and cirrhosis-related mortality, markedly increasing with the number of oral diseases present. These findings highlight the need for mechanistic research and intervention studies that will probably lead to improved clinical course and prognosis of cirrhosis.

Acknowledgments

The authors thank dental hygienists Nanna Jensen, Natasja Nielsen, and Susanne Hedegaard for performing clinical oral examinations and Dr Kristoffer Schwartz DDS at the Department of Oral and Maxillofacial Surgery, Aarhus University Hospital, Aarhus, Denmark, for performing the radiographic examinations. Lea Ladegaard Grønkjær received grants from Aarhus University Hospital, Aase & Ejnar Danielsens Foundation, A.P. Møller Foundation, Central Denmark Region Foundation for Health Research, and the Novo Nordisk Foundation. None of the other authors received any funds or has any financial interests to disclose.

References

- 1 Vargas CM, Arevalo O. How dental care can preserve and improve oral health. *Dent. Clin. N. Am.* 2009; **53**: 399–420.
- 2 Holmstrup P, Damgaard C, Olsen I *et al.* Comorbidity of periodontal disease: two sides of the same coin? An introduction for the clinician. *J. Oral Microbiol.* 2017; 9: 1–13.
- 3 Linden GJ, Lyons A, Scannapieco FA. Periodontal systemic associations: review of the evidence. J. Clin. Periodontal. 2013; 40 (Suppl. 14): S8–S19.

JGH Open: An open access journal of gastroenterology and hepatology 5 (2021) 294–300

© 2021 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

- 4 Ariyamuthu VK, Nolph KD, Ringdahl BE. Periodontal disease in chronic kidney disease and end-stage renal disease patients: a review. *Cardioremal. Med.* 2013; **3**: 71–8.
- 5 Gendron R, Grenier D, Maheu-Robert LF. The oral cavity as a reservoir of bacterial pathogens for focal infections. *Microbes Infect.* 2000; 2: 897–906.
- 6 Lins L, Bittencourt PL, Evangelista MA *et al*. Oral health profile of cirrhotic patients awaiting liver transplantation in the Brazilian Northeast. *Transplant. Proc.* 2011; **43**: 1319–21.
- 7 Movin S. Relationship between periodontal disease and cirrhosis of the liver in humans. J. Clin. Periodontol. 1981; 4: 450–8.
- 8 Castellanos-Cosano L, Machuca-Portillo G, Segura-Sampedro JJ *et al.* Prevalence of apical periodontitis and frequency of root canal treatments in liver transplant candidates. *Med. Oral Patol. Oral Cir. Bucal.* 2013; **18**: 773–9.
- 9 Helenius-Hietala J, Meurman JH, Höckerstedt K, Lindqvist C, Isoniemi H. Effect of the aetiology and severity if liver disease on oral health and dental treatment prior to transplantation. *Transpl. Int.* 2012; 25: 158–65.
- 10 Novacek G, Plachetzky U, Pötzi R *et al.* Dental and periodontal disease in patients with cirrhosis- role of etiology of liver disease. *J. Hepatol.* 1995; 22: 576–82.
- 11 Grønkjær LL, Holmstrup P, Schou S et al. Periodontitis in patients with cirrhosis: a cross-sectional study. BMC Oral Health. 2018; 18: 1–7.
- 12 Grønkjær LL, Holmstrup P, Schou S *et al.* Presence and consequence of tooth periapical radiolucency in patients with cirrhosis. *Hepat. Med.* 2016; **13**: 97–103.
- 13 Grønkjær LL, Holmstrup P, Schou S *et al.* Severe periodontitis and higher cirrhosis mortality. *United European Gastroenterol. J.* 2018; 6: 73–80.
- 14 Kim JK, Baker LA, Davarian S, Crimmins E. Oral health problems and mortality. J. Dent. Sci. 2013; 8: 115–20.
- 15 Willadsen TG, Siersma V, Nicolaisdottir DR *et al.* Multimorbidity and mortality. A 15-year longitudinal registry-based nationwide Danish population study. *J. Comorb.* 2018; 8: 1–9.
- 16 Quan H, Li B, Couris CM *et al*. Updating and validating the Charlson comorbidity using data from 6 countries. *Am. J. Epidemiol.* 2011; 173: 676–82.
- 17 Kondrup J, Allison SP, Elia M, Vellas B, Plauth M. ESPEN guidelines for nutrition screening 2002. *Clin. Nutr.* 2003; 22: 415–21.
- 18 Peng Y, Qi X, Guo X. Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. *Medicine (Baltimore)*. 2016; **95**: 1–29.
- 19 Frank L. When an entire country is a cohort. *Science*. 2000; 287: 2398–9.
- 20 Pedersen CB, Gøzche H, Møller J, Mortensen PB. The Danish civil registration system. A cohort of eight million persons. *Dan. Med. Bull.* 2006; **53**: 441–9.
- 21 Silness J, Loe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. *Acta Odontol. Scand.* 1964; 22: 121–35.
- 22 Page RC, Eke PI. Case definitions for use in population-based surveillance of periodontitis. J. Periodontol. 2007; 78(7 Suppl): 1387–99.
- 23 Lin LI. A concordance correlation coefficient to evaluate reproducibility. *Biometrics*. 1989; 45: 255–68.

- 24 McBrides GB. A proposal for strength-of-agreement criteria for Lin's Concordance Correlation Coefficient. 2005 NIWA Client Report: HAM 2005-062.
- 25 De Moor RJ, Hommez GM, De Boever JG, Delme KI, Mertens GE. Periapical health related to the quality of root canal treatment in a Belgian population. *Int. Endod. J.* 2002; **33**: 113–20.
- 26 Marubini E, Valsecchi MG. Competing risks. In: *Analysing Survival Data from Clinical Trials and Observational Studies*, 1st edn. Chichester: John Wiley & Sons, 1995; 331–63.
- 27 Jepsen P, Vilstrup H, Andersen PK, Sørensen HT. Socioeconomic status and survival of cirrhosis patients: a Danish nationwide cohort study. *BMC Gastroenterol.* 2009; **18**: 1–6.
- 28 Fialla AD, Schaffalitzky de Muckadell OB, Lassen AT. Incidence, etiology and mortality of cirrhosis: a population-based cohort study. *Scand. J. Gastroenterol.* 2012; **47**: 702–9.
- 29 Schmidt M, Schmidt SA, Sandegaard JL *et al*. The Danish national patient registry: a review of content, data quality, and research potential. *Clin. Epidemiol.* 2015; **17**: 449–90.
- 30 Petersen PE, Ogawa H. Strengthening the prevention of periodontal disease: the WHO approach. J. Periodontol. 2005; 76: 187–93.
- 31 Odesjo B, Hellden L, Salonen L. Prevalence of previous endodontic treatment, technical standard and occurrence of periapical lesions in a randomly selected adult, general population. *Endod. Dent. Traumatol.* 1990; 6: 265–72.
- 32 Grønkjær LL, Vilstrup H. Oral health in patients with liver cirrhosis. *Eur. J. Gastroenterol. Hepatol.* 2015; **27**: 834–9.
- 33 Forner L, Nielsen CH, Bendtzen K, Larsen T, Holmstrup P. Increased plasma levels of IL-6 in bacteremia periodontitis patients after scaling. J. Clin. Periodontol. 2006; 33: 724–729.36.
- 34 Forner L, Larsen T, Kilian M, Holmstrup P. Incidence of bacteremia after chewing, tooth brushing and scaling in individuals with periodontal inflammation. J. Clin. Periodontol. 2006; 33: 401–7.
- 35 Jensen A, Grønkjær LL, Holmstrup P *et al*. Unique subgingival microbiota associated with periodontitis in cirrhosis patients. *Sci. Rep.* 2018; 8: 1–15.
- 36 Mesas AE, De Andrade SM, Cabrera MA *et al*. Oral health status and nutritional deficit in non-institutionalized older adults in Londrina, Brazil. *Rev. Bras. Epidemiol.* 2012; 13: 1–11.
- 37 Åberg F, Helenius-Hietala J, Meurman J, Isoniemi H. Association between dental infections and the clinical course of chronic liver disease. *Hepatol. Res.* 2014; 44: 349–53.
- 38 Nagao Y, Kawahigashi Y, Sata M. Association of periodontal disease and liver fibrosis in patients with HCV and/or HBV infection. *Hepat. Mon.* 2014; 14: 1–7.
- 39 Sharma P, Dietich T, Ferro CJ et al. Association between periodontitis and mortality in stages 3-5 chronic kidney disease: NHANES III and linked mortality study. J. Clin. Periodontol. 2016; 43: 104–13.
- 40 Wu IJ, Chang TS, Hwang SL *et al.* Effects of oral hygiene programme and home phone counselling for hepatitis C patients receiving antiviral treatment. *J. Adv. Nurs.* 2018; **00**: 1–8.
- 41 Bajaj JS, Matin P, White M et al. Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2018; 315: G824–37.
- 42 Grønkjær LL. Periodontal disease and liver cirrhosis: a systematic review. SAGE Open Med. 2015; 9: 1–11.